Lung Cancer Clinical Trials in Salt Lake City

Showing 281-300 of 535 trials

Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung

NCT05987189

2,000 individuals, aged 50-80 who have received a lung-RADS category 3 or 4 result on a LDCT screening study and who are scheduled for follow-up diagnostic imaging study, biopsy, clinical consultation or surgical appointment at one of the participating hospitals.

Lung Cancer

Hummingbird Diagnostics2,000 participantsStarted Oct 2023

Atlanta, Georgia, United States • Boston, Massachusetts, United States • Detroit, Michigan, United States +5 more locations

COMPLETEDPhase 3< 1 mile

A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

NCT02864251

The main purpose of this study is to determine whether nivolumab + chemotherapy is effective as compared to chemotherapy in the treatment of patients with EGFR mutation, NSCLC who failed first line (1L) or second-line (2L) EGFR TKI therapy.

Non-Small-Cell Lung Carcinoma

Bristol-Myers Squibb367 participantsStarted Mar 2017

Long Beach, California, United States • Los Angeles, California, United States • Los Angeles, California, United States +106 more locations

Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung

A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

Lung Cancer Trials in Other Cities

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors

A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Prospective Clinicogenomic Program

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

Study of the CD40 Agonistic Monoclonal Antibody APX005M

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy

Survival Prolongation by Rationale Innovative Genomics

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Palliative Care Interventions for Outpatients Newly Diagnosed With Lung Cancer: Phase II

International Lung Screen Trial (ILST)

Other Conditions in Salt Lake City